Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
A Centers for Disease Control and Prevention committee voted 14-0-1 in favor of recommending that Pfizer Inc.'s COVID-19 vaccine can be safely used in 12- to 15-year-olds. The recommendation, made Wednesday by the CDC's Advisory Committee on Immunization Practices, follows a similar regulatory pathway as the original emergency-use authorization awarded in December. The expanded authorization for this age group was announced Monday by the Food and Drug Administration, the CDC committee voted Wedn...
Dr. Lakshman Swamy, ICU Physician at Cambridge Health Alliance and Boston Medical Center, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus pandemic.
A Centers for Disease Control and Prevention’s (CDC) advisory panel is scheduled to vote today on the use of Pfizer Inc’s (NYSE: PFE) and BioNTech SE’s (NASDAQ: BNTX) COVID-19 vaccine for kids aged 12 to 15. The meeting comes two days after the FDA approved the emergency use of Pfizer/BioNTech’s COVID-19 vaccine in adolescents aged between 12 to 15 years. The meeting is scheduled to run from 11 a.m. ET to 5 p.m. ET. Before the vote, medical experts will assess Pfizer and BioNTech’s clinical tria...
The European Commission president has provided some hints that a supply agreement with Novavax could be on the way.
Pfizer Inc has formally asked the UK medical regulator for permission to use its COVID-19 vaccine for 12-to 15-year olds in Britain, the Telegraph reported on Tuesday. Pfizer and the MHRA did not immediately response to Reuters requests for comment. The move comes as U.S. regulators on Monday authorized Pfizer and BioNTech's COVID-19 vaccine for use in children as young as 12, widening the country's inoculation program as vaccination rates have slowed significantly.
Despite some good news recently about the coronavirus vaccine it co-developed, BioNTech (NASDAQ: BNTX) has been hit with a recommendation downgrade. In a research note published on Tuesday, Bryan Garnier analyst Olga Smolentseva changed her view on the stock to neutral from the previous buy recommendation. At the same time, though, she significantly raised her price target on the stock, from $135 per share to $206.
Parents are pleased, but the move won't change much for the drug companies from a financial perspective.
Administration medical adviser Anthony Fauci told a Senate panel that steps to vaccinate younger children will probably occur in stages, progressing younger and younger, as study evidence accumulates.